Skip to main content
SpringerLink
Log in

Alogliptin EXAMINEd: no increased risk of heart failure outcomes

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet : 10 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)62225-X

    PubMed  Google Scholar 

  2. Standl E, et al. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet : 10 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(15)60037-X

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alogliptin EXAMINEd: no increased risk of heart failure outcomes. Reactions Weekly 1543, 9 (2015). https://doi.org/10.1007/s40278-015-8633-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-8633-1

Search

Navigation